Search
Showing results for "early lung health"
On this Research Impact page, learn about our work that's actively translated as Government policy or in active practice. Learn how our research is making a difference in people's lives - not tomorrow, next week, or next year - but today!
On this Research Impact page, we list stories helping demonstrate how we collaborate with other leaders, innovators, communities, and international stakeholders to ensure excellent research results. The better our results, the better the chances of research making a real difference.
News & Events
Research to help identify which children will develop asthma and to design more specific asthma treatments supported by Federal Government fundingResearch focussed on identifying which children will develop asthma, and developing more specific asthma treatments, has been supported by the National Health and Medical Research Council’s (NHMRC) Ideas Grants announced by the Federal Government on 14 December 2022.
ORIGINS has several sub-projects exploring allergy development within the cohort, with a focus on nutritional strategies for allergy prevention.
Research
A 15-Year Old Burmese Girl With Hemoptysis: A Case ReportA 15 year old girl, born in Hakha, Myanmar, presented with 2 months of intermittent hemoptysis 3 years after immigrating to Australia, via Malaysia.
Dr Anthony Bosco, Professor Steve Stick, Professor Andrew Whitehouse, Dr Raelene Endersby and Dr Luke Garratt know how fortunate they are to have
Research
Determining the off-target effects of infant vaccines on respiratory infection outcomes in Western Australian childrenChristopher Hannah Lea-Ann Blyth Moore Kirkham MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD PhD Centre Head, Wesfarmers Centre
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Research
Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infantsPapua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity.
Research
Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocolWe aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.